A Randomized, Double-blind, Single Dose, Placebo-controlled, 5-Period, 5-Treatment, Crossover, Multi-center, Dose-ranging Study to Compare PT007 to Placebo MDI and Open-Label Proventil HFA in Adult and Adolescent Subjects With Mild to Moderate Asthma
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2018
At a glance
- Drugs Salbutamol (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors AstraZeneca; Pearl Therapeutics
- 04 Apr 2018 Status changed from active, no longer recruiting to completed.
- 13 Mar 2018 Planned End Date changed from 9 May 2018 to 28 Mar 2018.
- 13 Mar 2018 Planned primary completion date changed from 9 May 2018 to 28 Mar 2018.